A B S T R A C T The site of synthesis of Hageman factor (HF, Factor XII) has not been previously demonstrated with certainty. We have studied the production and release of HF in the isolated perfused rat liver and have compared rates of synthesis in this system with absolute rates of degradation measured in vivo. Rat livers, perfused for 5 h with a recycling fluid consisting of a perfluorochemical emulsion (Fluosol 43), were used to demonstrate a cumulative increase of HF in the perfusate as measured by a specific and sensitive radioimmunoassay. The rate of increase in the perfusate pool of HF during the final 4 h of perfusion yielded a mean synthetic rate of 3.5 Ag/h per 100 g body wt, which was -0.2% of the synthetic rate of albumin in the same system. The cumulative appearance of albumin and transferrin was linear after 1 h and calculated rates of synthesis were 2,012 tg/h per 100 g and 263 tsg/h per 100 g body wt, respectively.
INTRODUCTION
Hageman factor (HF', Factor XII) is a plasma protein with an approximate molecular weight of 80,000 present in the blood of most mammals. Under certain conditions HF triggers several contact-activated plasma reactions such as blood coagulation, kinin generation, and fibrinolysis (2) . The normal concentration of HF in human plasma is -3-4 mg/dl (3) and the plasma half-life of HF in man has been reported to be -50-60 h following the infusion of normal plasma into individuals with hereditary HF deficiency (4) . The site of synthesis of HF is not known with certainty, although earlier observations have indirectly suggested that the liver may be a site of production and secretion.
In this study we have purified HF from rat plasma and raised a monospecific antiserum against rat HF in rabbits, which has enabled us to develop a specific and sensitive radioimmunoassay for rat HF. By means of this assay we have shown that isolated perfused rat liver produces and releases HF into the circulation. De novo synthesis of HF was confirmed by demonstrating the incorporation of ['4C]lysine into specific immunoprecipitates of HF derived from the circulating perfusate, and by inhibition of synthesis by cycloheximide. Furthermore, we have measured the half-disappearance time of radioiodine-labeled HF in intact rats and have estimated its absolute catabolic rate, which agrees closely with the rates of synthesis determined in vitro in the isolated perfused liver. METHODS Procoagulant activities measurement. The procoagulant activities of HF (Factor XII), plasma thromboplastin antecedent (Factor XI), prekallikrein, high-molecular-weight kininogen, Christmas factor (Factor IX), and antihemophilic factor (AHF, Factor VIII) were measured by the kaolin-activated partial thromboplastin time using congenital-deficient plasma as substrate (5, 6) .
Isolation and characterization of rat HF. Rat HF was isolated from 700 ml of pooled plasma from Sprague-Dawley rats (Pel Freez Biologicals, Rogers, AR) by a method described for human HF (7). The purified preparation had a specific activity of 22 units/mg protein (1 unit being defined as that amount present in 1.0 ml of pooled rat plasma) and it showed a single stained protein band on analytical polyacrylamide disc gel electrophoresis (8) . This band contained clot-promoting activity for human HF-deficient plasma, as tested by assaying eluates from 1-mm segments of replicate gels (Fig. 1) . Upon sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (9) rat HF yielded a single major protein band in the presence and absence of a reducing agent, 2-mercaptoethanol (Fig. 2) . The same protein band also yielded a positive periodic acid-Schiff stain (10) . The apparent molecular weight of rat HF was -80,000 and isoelectric focusing (11) revealed a pI of 5.1-5.5. These results suggest that rat HF is a single-chain glycoprotein with a molecular weight of -80,000, similar to human and bovine HF (12, 13) . The amino acid composition of rat HF is also very similar to that of human HF (Table I) .
Anti-rat HF serum. Anti-rat HF serum was raised in New
Zealand albino rabbits by injections of purified rat HF. Upon Ouchterlony immunodiffusion, this antiserum showed a single precipitin line of complete identity with purified rat HF and rat plasma (Fig. 3) . Furthermore, the antiserum selectively blocked HF clot-promoting activity without significant inhibition of activities of other clotting factors (Table  II) . These results indicate that this antiserum contains antibodies that are monospecific immunologically and functionally. A crude immunoglobulin fraction of the antiserum was isolated as described earlier (14) . was tested in this assay, similar displacement curves were obtained (Fig. 4) . The assay is sensitive to 0.05 sg HF/ml or 0.125% of the concentration of HF present in normal pooled rat plasma. The concentration of HF present in rat plasma was estimated to be -40 Ag/ml compared to a stan- Synthesis of Hageman Factor FIGURE 3 Immunodiffusion study of anti-rat HF serum (3) against rat plasma (2) and purified rat HF (1).
dard curve using purified rat HF. This titer is very close to that found in normal human plasma (3) . Liver perfusion studies. Livers isolated from fed male Sprague-Dawley rats (400-500 g body wt) were perfused through the portal vein with recycling perfusate (-80 In some experiments, all glass surfaces in the perfusion system were washed with 100 ug/ml of hexadimethrine bromide (Polybrene, Aldrich Chemical Co. Inc., Milwaukee, WI) and rinsed with deionized water before use. Samples of perfusate (3-5 ml) were withdrawn at hourly intervals and centrifuged at 12,000 g for 30 min to sediment the suspended perfluorochemicals. The clear supernatant, to which aprotinin (Sigma Chemical Co., St. Louis, MO) was added (10 units/ml), was assayed for HF by RIA and for albumin and transferrin by radial immunodiffusion (15) . Preliminary experiments showed that rat HF added to the fluorocarbon suspension was completely recovered in the supernatant and that the presence of the supernatant or cycloheximide in the assay mixture did not interfere with the RIA. Assay of HF standards gave identical results in the presence or absence of the fluorocarbon supernatant. The rates of HF, albumin, and transferrin production and release, expressed as micrograms per hour per 100 g body wt, were calculated from the rate of increase in the size of the respective cumulative pools, which was obtained by multiplying the perfusate specific protein concentration by the supernatant volume, with allowance made for previous sampling.
Effect of cycloheximide upon production and release of HF. In four experiments, cycloheximide was added to the perfusate after 1 h to give a final concentration of 18 uM. This concentration of cycloheximide has previously been shown to inhibit albumin and plasminogen synthesis and release in the isolated perfused rat liver (16) .
Incorporation of ['4C]lysine into HF. In five experiments, 50,Ci of L-["4C(U)]lysine (>300 mCi/mmol, New England Nuclear, Boston, MA) was added to the reservoir at the start of the perfusion. After 5 h of perfusion, -40 ml of perfusate supernatant containing free and incorporated
[14C]lysine was exhaustively dialyzed against 1 mM nonradioactive lysine in barbital-saline buffer (0.025 M sodium barbital, 0.125 M sodium chloride, pH 7.4). 1 ml of human HF-deficient plasma was added, as a source of carrier proteins, to 10 ml of dialyzed perfusate and the 0-60% ammonium sulfate fraction was precipitated. The precipitate was dissolved in barbital-saline buffer, dialyzed against the same buffer, and divided in two aliquots. One aliquot was incubated with 0.025 ml of rabbit anti-rat HF IgG (17.5 mg/ ml) for 1 h at 370C and then overnight at 4°C. The other aliquot was incubated with normal rabbit IgG (17.0 mg/ml) in a similar manner. Goat anti-rabbit IgG serum, 0.1 ml (Antibodies Inc., Paris, CA) was then added to each tube and the mixtures were incubated overnight at 4°C. The resulting immunoprecipitates were centrifuged and washed three times with ice-cold saline. The washed immunoprecipitates were dissolved in 0.3 ml of hyamine hydroxide (New England Nuclear) and counted in a liquid scintillation spectrometer after the addition of Aquasol scintillator (New England Nuclear). The results were expressed as a percentage of the radioactivity in immunoprecipitates relative to that contained in the initial ammonium sulfate-precipitated protein fraction. Mg/ml and a plasma volume of 3.8 ml/100 g body wt (18) .
RESULTS
Appearance of HF in the perfusate. The amount of HF present in the perfusate increased progressively during 5 h of perfusion (Fig. 5) "C-radioactivity in the specific immunoprecipitates (4.1±1.0%, mean±SEM) than in the control immunoprecipitates (1.8±0.4%, P < 0.025) (Table III) . Furthermore, the addition of cycloheximide virtually abolished the incorporation of "C-radioactivity into both specific and control immunoprecipitates. Absolute catabolic rate of HF. The plasma decay curve for the mean catabolic data is shown in Fig. 7 . The two exponentials yielded plasma half-lives of 1.4 and 27.0 h, respectively. Since it was apparent. that plasma HF radioactivity had fallen to -14.5% of the 10-min value after -4 h, it was difficult to explain the initial rapid decay on the basis solely of distribution kinetics. It seems likely that other nonidentified routes of loss, including rapid degradation of some HF denatured in the purification process, were responsible for early disappearance. Therefore, the terminal slower exponential was used to calculate and approximate fractional catabolic rate, on the assumption that this represented the degradation of residual native HF. The mean rate constant of this exponential was 0.026/ h. The mean absolute catabolic rate calculated from this on the basis of a plasma volume of 3.8 ml/100 g body wt (18) was 4.0 ,g/h per 100 g.
DISCUSSION
The present study was designed to determine the role of the liver in the synthesis of HF by a method that avoids the nonspecificity of functional assay techniques. As such, it confirms and extends the observations of Owen and Bowie (19, 20) that the prolonged clotting time of human HF-deficient plasma can be corrected by the addition of perfusate from isolated rat liver. However, since the liver produces many clotting factors (19) , such a functional assay may be affected by the presence of other activated procoagulants released by the liver. In contrast, the present studies evaluated the presence of newly synthesized HF, quantified its rate of synthesis by a RIA, and correlated The validity of our data is intrinsically dependent upon the specificity of the rabbit anti-rat HF serum and RIA technique used. The rat HF used for immunization and for the RIA was judged to be a single homogeneous protein on disc gel electrophoresis, SDS-PAGE, and immunodiffusion studies. Amino acid analysis of this preparation was very similar to that of human HF. Furthermore, the anti-rat HF serum raised in rabbits showed a single precipitin line of complete identity with both purified rat HF and whole rat plasma. Similarly, the monospecificity of this source of antibodies was confirmed by demonstrating that the slopes of the displacement curves for both rat plasma and purified HF were identical.
The liver perfusion system used a chemically defined artificial Krebs-Ringer bicarbonate perfusate in which 02 transport and delivery was the property of a perfluorocarbon, and oncotic pressure was exerted by hydroxyethyl starch. Thus, the possibility that HF is generated by contaminating blood cells (21) is unlikely. A similar preparation has been shown to maintain viability of the perfused liver for at least 5 h (22) , and previous studies in this laboratory have demonstrated that the liver in this system synthesizes plasminogen at physiologic rates (16) . Furthermore, similar rates of production of albumin were observed in the present study, as were found in an earlier study that used a more physiological perfusate of plasma and erythrocytes (23) . In addition, it is apparent that although the initial rate of appearance of HF in the perfusate is rapid and may be partially accounted for by release of preformed protein, the linear appearance of HF over the subsequent 240 min represents de novo synthesis of protein. This was confirmed by the efficacy of cycloheximide, an inhibitor of protein synthesis, in almost totally abolishing the appearance of HF within 60 min of administration.
Finally, an attempt was made to use the incorporation of ['4C]lysine into HF as qualitative evidence for de novo synthesis. In these experiments the entire 300-min perfusate was harvested for double-antibody immunoprecipitation of labeled HF. To allow for nonspecific coprecipitation of other labeled proteins of liver origin present in the ammonium sulfate fraction, a control precipitation was carried out by adding normal rabbit IgG to an equal aliquot followed by goat anti-rabbit IgG. The percent radioactivity precipitated by the specific anti-HF IgG was significantly higher in all five experiments. In other words, the difference in radioactivity incorporated in these two groups of immunoprecipitates represents [14C]lysine specifically incorporated into HF. Furthermore, this specific incorporation was also inhibited by cycloheximide.
The hepatic synthetic rate of HF of 3.5 gg/h per 100 g body wt calculated from the rate of increase in the cumulative pool of HF in the isolated perfused rat liver is in close agreement with the estimated absolute rate of catabolism measured in vivo of 4.0 ,ug/h per 100 g. Although the latter calculation is based upon the slowest component of the plasma half-life; it has been argued that such a method can be expected to yield very similar results to that obtained from measurements of whole body radioactivity (24) . The close agreement between this calculated rate of degradation and the rate of synthesis observed in the perfusion system leads us to conclude that the liver is the principal site of HF synthesis and secretion in the rat.
